Carmat : Ajustement des prévisions à la baisse, refinancement obligatoire à CT
>Guidance 2024 revue à la baisse - Carmat publie ce matin ses résultats semestriels. Nous connaissions déjà les ventes du groupe pour la période qui ressortent à 3,3 M€ (ajustée à la hausse car annoncées en juillet à 3,2 M€). Ce chiffre correspond à la vente de 20 cœurs artificiels Aeson dont 7 dans le cadre commercial (Allemagne, Italie et Pologne) et 13 dans le cadre de l’étude EFICAS en France. Suite à ce début d’année, le management abaisse sa guidance annuel...Carmat is focused on the research and development of an innovative product in the medical sector, developing an orthotopic and biocompatible artificial heart which is completely implantable, as well as its electrical power supply system and remote diagnosis system. Co. is developing a long-term therapeutic solution for patients who suffer from advanced bi-ventricular heart failure and who are not eligible for cardiac transplantation and who have exhausted all drug possibilties. Co. is still in the phase of research and development and thus do not generate any revenues.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.